Literature DB >> 6882665

Enhancement of the action of alkylating agents by single high, or chronic low doses of misonidazole.

N J McNally, M Hinchliffe, J de Ronde.   

Abstract

Misonidazole (MISO) given as a large single dose enhanced the action of cyclophosphamide (Cy) and melphalan (L-PAM) in two mouse tumours. Below a dose of about 500 mg kg-1 it had no chemosensitizing effect. When MISO was given as a series of small doses by repeat injection over an 8 h period, in order to stimulate human pharmacokinetics, it significantly enhanced the action of Cy in the SA F tumour. It also enhanced the action of Cy and L-PAM in the WHFIB tumour as assayed by tumour cell survival in vitro following treatment in vivo but not when the assay was tumour growth delay. There was no enhancement by MISO of the leukopenia due to Cy or L-PAM. The results suggest that, in some tumours there may be benefit from the combination of clinically relevant MISO doses with alkylating agents. The leucopenia induced by these agents should not be enhanced by the MISO.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6882665      PMCID: PMC2011437          DOI: 10.1038/bjc.1983.182

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  14 in total

1.  Radiosensitizing and toxic effects on the 2-nitroimidazole Ro-07-0582 in hypoxic mammation cells.

Authors:  B A Moore; B Palcic; L D Skarsgard
Journal:  Radiat Res       Date:  1976-09       Impact factor: 2.841

2.  The magnitude of hypoxic cell cytotoxicity of misonidazole in human tumours.

Authors:  J Denekamp; N J McNally
Journal:  Br J Radiol       Date:  1978-09       Impact factor: 3.039

3.  Misonidazole cytotoxicity in vivo: a comparison of large single doses with smaller doses and extended contact of the drug with tumor cells.

Authors:  P J Conroy; R M Sutherland; W Passalacqua
Journal:  Radiat Res       Date:  1980-07       Impact factor: 2.841

4.  Recovery from sublethal damage by acutely hypoxic tumour cells in vivo and in vitro.

Authors:  N J McNally; K C George; J de Ronde
Journal:  Br J Radiol       Date:  1979-08       Impact factor: 3.039

Review 5.  The mechanisms of cytotoxicity and chemosensitization by misonidazole and other nitroimidazoles.

Authors:  J M Brown
Journal:  Int J Radiat Oncol Biol Phys       Date:  1982 Mar-Apr       Impact factor: 7.038

6.  Studies on the mechanism of chemosensitization by misonidazole in vitro.

Authors:  Y C Taylor; E A Bump; J M Brown
Journal:  Int J Radiat Oncol Biol Phys       Date:  1982 Mar-Apr       Impact factor: 7.038

7.  The effect of cytotoxic drugs with or without misonidazole on leucopenia in three strains of mice.

Authors:  N J McNally; T C Stephens; P R Twentyman; M Hinchliffe; J H Peacock; D Spooner
Journal:  Int J Radiat Oncol Biol Phys       Date:  1982 Mar-Apr       Impact factor: 7.038

8.  Clinical phase I study of the hypoxic cell radiosensitizer RO-07-0582, a 2-nitroimidazole derivative.

Authors:  R C Urtasun; P Band; J D Chapman; H R Rabin; A F Wilson; C G Fryer
Journal:  Radiology       Date:  1977-03       Impact factor: 11.105

9.  Effect of hyperthermia on cytotoxicity of the radiosensitizer Ro-07-0582 in a solid mouse tumour.

Authors:  K C George; D G Hirst; N J McNally
Journal:  Br J Cancer       Date:  1977-03       Impact factor: 7.640

10.  An investigation of the possibility of chemosensitization by clinically achievable concentrations of misonidazole.

Authors:  P R Twentyman; P Workman
Journal:  Br J Cancer       Date:  1983-02       Impact factor: 7.640

View more
  8 in total

1.  Distribution of nitroimidazoles and L-phenylalanine mustard in mammary adenocarcinoma 16/C tumors.

Authors:  P E Noker; L Simpson-Herren; S D Wagoner
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

2.  Potentiation of CCNU activity by misonidazole in metastases.

Authors:  D W Siemann; K L Alliet
Journal:  Clin Exp Metastasis       Date:  1987 Jan-Mar       Impact factor: 5.150

3.  Altered pharmacokinetics in the mechanism of chemosensitization: effects of nitroimidazoles and other chemical modifiers on the pharmacokinetics, antitumour activity and acute toxicity of selected nitrogen mustards.

Authors:  F Y Lee; P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

4.  Misonidazole reduces blood flow in two experimental murine tumours.

Authors:  J C Murray; V S Randhawa
Journal:  Br J Cancer       Date:  1988-08       Impact factor: 7.640

5.  Sensitization of normal and malignant tissue to cyclophosphamide by nitroimidazoles with different partition coefficients.

Authors:  D G Hirst; J L Hazlehurst; J M Brown
Journal:  Br J Cancer       Date:  1984-01       Impact factor: 7.640

6.  Factors influencing the chemosensitization of melphalan by misonidazole.

Authors:  V S Randhawa; F A Stewart; J Denekamp; M R Stratford
Journal:  Br J Cancer       Date:  1985-02       Impact factor: 7.640

7.  Effect of the nitroimidazole Ro 03-8799 on the activity of chemotherapeutic agents against a murine tumour in vivo.

Authors:  P W Sheldon; P Gibson
Journal:  Br J Cancer       Date:  1984-03       Impact factor: 7.640

8.  The effect of radiosensitizers on the pharmacokinetics of melphalan and cyclophosphamide in the mouse.

Authors:  M Hinchliffe; N J McNally; M R Stratford
Journal:  Br J Cancer       Date:  1983-09       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.